Questions For Senators to Ask Drs. Marty Makary and Jay Bhattacharya

Senate hearings are often treated like political talent shows: everyone gets five minutes, somebody says “the American people deserve answers,” and a witness tries to look calm while wondering whether the next question will involve a chart, a scandal, or a sentence pulled from an old television interview.

But when the nominees are doctors being considered for leadership roles connected to the Food and Drug Administration and the National Institutes of Health, the stakes are much bigger than a viral clip. FDA decisions affect the safety of drugs, vaccines, food, medical devices, tobacco products, and emerging treatments. NIH decisions shape the research pipeline that may eventually change how Americans prevent disease, manage chronic illness, and respond to future public-health emergencies.

Dr. Marty Makary and Dr. Jay Bhattacharya both became prominent figures in debates about public health, medical institutions, scientific transparency, COVID-era policy, and public trust. Their supporters often see them as doctors willing to challenge bureaucracy and groupthink. Their critics worry that skepticism of institutions can become skepticism of the evidence those institutions are meant to evaluate.

That tension is exactly why senators should ask sharper questions. Not louder questions. Not “gotcha” questions engineered for a campaign email. Sharp questions that force nominees to explain how they will make decisions when science is messy, politics is loud, and real patients are waiting for answers.

Why Senate Questions Matter More Than Hearing-Day Headlines

A useful confirmation hearing should test judgment, not just résumé polish. The best questions reveal how a nominee thinks when there is no perfect answer waiting in a binder.

For FDA and NIH leadership, senators should focus on three things: independence, evidence standards, and accountability. A nominee should be able to explain how they would protect career scientists from political pressure, how they would distinguish preliminary research from reliable evidence, and how the public could measure whether promised reforms actually happened.

That is particularly important when a nominee has built a public profile around challenging mainstream opinion. Contrarian thinking is not automatically reckless. Medicine has improved many times because someone asked, “Are we sure this is working?” But the job of a federal health leader is not simply to challenge consensus. It is to build a process that can tell the difference between a useful challenge and a bad idea wearing a lab coat.

Questions Senators Should Ask Dr. Marty Makary

1. “What evidence threshold will you use before changing an FDA policy?”

Senators should ask Dr. Makary how he would decide when an FDA policy needs revision. Would a new policy require randomized clinical trial data? Large observational studies? Post-market safety reports? A public advisory committee? Or would a collection of headlines and anecdotes somehow become enough?

A strong answer should include a clear framework: identify the evidence, publish the reasoning, allow career scientists to document disagreement, and explain why the final decision was made. “I will follow the science” is not a framework. It is a bumper sticker. Senators should ask what the actual process looks like when the science points in several directions at once.

2. “How will you protect FDA scientists from political interference?”

The FDA exists partly to keep scientific review from becoming a political popularity contest. That role can become difficult when a decision involves vaccines, reproductive-health medications, tobacco products, weight-loss drugs, food additives, or treatments that attract enormous public attention.

Senators should ask whether FDA reviewers would be able to publish dissenting analyses, whether advisory committee meetings would remain transparent, and whether political officials could overrule scientists without leaving a public record. The question is not whether an agency leader may disagree with staff. Leaders do that all the time. The question is whether disagreement will be documented honestly instead of disappearing into a filing cabinet with the expired office snacks.

3. “How will you balance faster approvals with patient safety?”

Patients with rare diseases, aggressive cancers, and serious neurological conditions often cannot wait years for a treatment to crawl through the approval process. At the same time, faster approval can create risk if benefits are overstated or safety questions are pushed aside.

Senators should ask Dr. Makary how he would use accelerated approval pathways, especially for therapies supported by early evidence. What post-market studies would companies be required to complete? What happens when those studies fail? Would the FDA remove a treatment promptly if promised benefits do not materialize? The public deserves both urgency and rigor; “pick one” should not be the agency’s business model.

4. “What will transparency mean in practice?”

Calls for transparency are popular because nobody wants to campaign on a platform called “More Fog, Less Accountability.” But transparency has to mean more than posting a press release after the decision is already made.

Senators should ask whether Dr. Makary would support public decision memos for major FDA actions, searchable records of advisory committee conflicts, accessible summaries of safety data, and timely explanations when a public meeting is delayed or canceled. Transparency matters most before trust collapses, not after everyone is arguing online at midnight.

5. “How will you handle politically sensitive medicines?”

Some FDA-regulated products sit at the center of national political battles. That is unavoidable. What is avoidable is allowing political pressure to replace evidence review.

Senators should ask Dr. Makary to explain how he would review controversial medicines without prejudging the outcome. Would he rely on the same standards for evidence, safety monitoring, expert review, and public explanation that he would use for any other drug? A credible FDA leader should be able to say, clearly, that the evidence standard does not change because a topic appears on cable news.

6. “How will you measure whether FDA reforms help ordinary Americans?”

Reform can sound impressive even when it is mostly a new logo, a five-page slogan, and a conference room full of people saying “innovation” every six minutes. Senators should ask for measurable benchmarks.

How long will drug reviews take? How quickly will safety signals be evaluated? How many food inspections will be completed? How will the agency report shortages, recalls, and enforcement actions? What will happen to staffing levels in divisions responsible for food safety, medical devices, and drug quality? The public should be able to judge results without needing a decoder ring.

Questions Senators Should Ask Dr. Jay Bhattacharya

1. “How will you protect scientific dissent without rewarding weak evidence?”

Dr. Bhattacharya has argued that public health institutions need more openness to scientific disagreement. That is a fair subject for Senate scrutiny because scientific progress depends on debate, replication, and the willingness to challenge assumptions.

But senators should press for specifics. How will NIH distinguish a serious dissenting hypothesis from a claim that lacks credible evidence? Will scientists be encouraged to debate methods and data publicly? Will NIH still require strong study design, reproducible findings, and peer review? Free inquiry is valuable, but it should not become a free pass for every theory that arrives with a microphone.

2. “What is your plan to strengthen research reproducibility?”

NIH-funded research influences medical practice, pharmaceutical development, and public confidence in science. When studies cannot be reproduced, the consequences are more than academic embarrassment. Patients may lose time, money, hope, or access to better treatments.

Senators should ask Dr. Bhattacharya whether he supports stronger data-sharing requirements, preregistration for certain studies, independent replication grants, clearer reporting of negative results, and improved statistical training. The goal should not be to punish researchers. It should be to make good science easier to identify and weaker science harder to oversell.

3. “How will you protect NIH grants from political favoritism?”

NIH research funding supports universities, hospitals, community health systems, early-career scientists, and laboratories across the country. Senators should ask how Dr. Bhattacharya would ensure that grants are awarded based on scientific merit rather than political alignment, institutional popularity, or social-media controversy.

A direct question could be: “Will you commit to publishing clear, stable criteria for grants and explaining major changes in funding priorities before they are implemented?” That is not glamorous, but neither is checking the expiration date on milk. Both are extremely important when the consequences land in someone else’s body or budget.

4. “How will you balance chronic-disease research with basic science?”

Bhattacharya has emphasized chronic disease, including conditions such as obesity, diabetes, cancer, heart disease, and neurological illness. Those priorities reflect urgent health needs. Still, senators should ask whether an increased focus on immediate disease burdens could unintentionally weaken basic science.

Many medical breakthroughs begin with research that seems distant from a patient’s bedside: cell biology, genetics, immunology, chemistry, or computational modeling. The NIH should not have to choose between solving today’s health problems and discovering tomorrow’s tools. Senators should ask how the agency would protect both missions.

5. “What standards will guide vaccine and infectious-disease research?”

Public trust in vaccines and pandemic preparedness has become politically fragile. That makes clarity more important, not less. Senators should ask how Dr. Bhattacharya would ensure that NIH-supported research on vaccines, emerging infections, and public-health interventions uses transparent methods and independent review.

The central question should be simple: when evidence is strong, will NIH communicate that strength plainly? When evidence is uncertain, will NIH explain the uncertainty without exaggeration? Trust grows when institutions tell the public what they know, what they do not know, and what they are doing next to find out.

6. “How will you oversee high-risk research safely?”

Research involving dangerous pathogens can offer valuable scientific insight, but it also raises legitimate concerns about laboratory safety, biosecurity, and public accountability. Senators should ask Dr. Bhattacharya how NIH would define high-risk work, who would review it, and what safeguards would be required before funding is approved.

He should be asked whether review decisions would be transparent enough for the public to understand the rationale while still protecting genuinely sensitive security information. “Trust us” is not a risk-management plan. It is what people say when they have misplaced the actual plan.

Questions Both Doctors Should Be Asked

Senators should also ask both doctors a shared set of questions because FDA and NIH decisions often intersect. NIH funds the research that may lead to new therapies. FDA evaluates whether those therapies are safe and effective enough for patients. If the agencies operate with incompatible standards, patients get confusion instead of confidence.

“Will you publish a 100-day and one-year accountability plan?”

Both leaders should be asked to publish practical goals that can be reviewed by Congress and the public. These goals could include staffing targets, transparency reforms, research-quality initiatives, advisory committee procedures, and patient-access measures.

“Will you disclose meetings with regulated industries and major outside stakeholders?”

Industry expertise can be useful. Patient groups can be essential. Academic researchers can provide critical perspective. But the public needs to know who has access to agency leaders, what issues were discussed, and whether conflicts of interest were disclosed.

“How will you communicate uncertainty without losing public trust?”

This may be the hardest question of all. Science changes when better evidence appears. A responsible leader must be willing to revise a position without pretending the earlier uncertainty never existed. The public can handle nuance. What people struggle to forgive is being treated like they cannot.

What Oversight Looks Like in Real Life: Experiences Beyond the Hearing Room

It is easy to think of FDA and NIH oversight as a Washington activity involving microphones, hearing rooms, thick binders, and senators who somehow always appear to have a perfectly timed dramatic pause. But the real consequences appear far away from Capitol Hill.

Consider the parent of a child with a rare disease. That parent may spend years learning unfamiliar medical vocabulary, comparing trial results, fundraising for travel, and waiting for a treatment that may or may not reach the market. For that family, a faster FDA review process could mean hope. But a weak review process could mean false hope, financial strain, and a painful delay before the truth becomes clear. Senators should remember that every conversation about “innovation” eventually lands in a living room.

Then there is the early-career scientist whose NIH grant determines whether a laboratory stays open. That researcher may be studying a disease that is not fashionable, profitable, or easily explained in a thirty-second video. Stable, merit-based funding can allow that scientist to pursue an idea that later becomes a major breakthrough. Sudden rule changes, opaque funding priorities, or political tests can make talented researchers leave public science altogether.

Community physicians experience these policies differently. A doctor in a rural clinic may see patients who cannot travel to a specialist, cannot afford an experimental therapy, and may distrust public-health guidance because they have heard five competing versions online. That doctor needs federal agencies to provide information that is clear, accurate, timely, and understandable. Scientific communication is not a luxury. It becomes part of patient care.

FDA career reviewers and NIH program officers also live with the consequences of leadership decisions. They are the people reading trial data, reviewing grant applications, inspecting facilities, tracking adverse events, and answering difficult questions when the public wants certainty immediately. When political leaders make a public promise that ignores the evidence, those staff members are left trying to repair trust with fewer tools and more scrutiny.

Patients, researchers, clinicians, agency staff, and families do not need perfect federal leaders. Nobody is perfect, especially not in Washington, where perfection is usually announced at a podium before lunch and revised by dinner. What they need are leaders who can explain their reasoning, accept criticism, protect evidence-based decision-making, and admit when a policy must change.

That is why Senate questioning matters. A hearing should not be the end of accountability. It should be the beginning of a public record that senators, journalists, physicians, patients, and taxpayers can revisit when policies move from promise to practice.

Conclusion: Better Questions Create Better Public Health Oversight

Dr. Marty Makary and Dr. Jay Bhattacharya represent a larger debate about public trust, scientific institutions, and the role of dissent in medicine. Senators should not approach that debate as a partisan cage match. They should approach it as a test of whether federal health leaders can combine independence with responsibility.

The best questions are concrete: What evidence will guide decisions? Who can challenge a decision? How will conflicts be disclosed? What happens when data changes? How will patients know whether reform is helping? These are not glamorous questions, but they are the questions that protect the public long after the hearing-room cameras are gone.